Dapiprazole HCl
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 540098

CAS#: 72822-13-0 (HCl)

Description: Dapiprazole HCl is an α1-Adrenergic receptor antagonist used to reverse mydriasis. It also decreases mean intraocular pressure, suppresses pigment shedding, and increases outflow facility.


Price and Availability

Size
Price

10mg
USD 210
Size
Price

50mg
USD 650
Size
Price

Dapiprazole HCl, purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received. CoA, QC data and MSDS documents are available in one week after order is received.


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 540098
Name: Dapiprazole HCl
CAS#: 72822-13-0 (HCl)
Chemical Formula: C19H28ClN5
Exact Mass: 361.2033
Molecular Weight: 361.91
Elemental Analysis: C, 63.06; H, 7.80; Cl, 9.80; N, 19.35


Related CAS #: 72822-12-9 (free base)   72822-13-0 (HCl)    

Synonym: AF 2139; AF2139; AF-2139; Dapiprazole HCl

IUPAC/Chemical Name: 3-(2-(4-(o-tolyl)piperazin-1-yl)ethyl)-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyridine hydrochloride

InChi Key: ZIODNPFQZIHCOE-UHFFFAOYSA-N

InChi Code: InChI=1S/C19H27N5.ClH/c1-16-6-2-3-7-17(16)23-14-12-22(13-15-23)11-9-19-21-20-18-8-4-5-10-24(18)19;/h2-3,6-7H,4-5,8-15H2,1H3;1H

SMILES Code: CC1=CC=CC=C1N2CCN(CCC3=NN=C4CCCCN43)CC2.[H]Cl


Technical Data

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:
293490


References

1: Hogan TS, McDaniel DD, Bartlett JD, Hart KK, Paggiarino DA. Dose-response study of dapiprazole HCl in the reversal of mydriasis induced by 2.5% phenylephrine. J Ocul Pharmacol Ther. 1997 Aug;13(4):297-302. PubMed PMID: 9261765.

2: Silvestrini B, Lisciani R, Baldini A, de Sanctis AJ. Psychopharmacological profile of dapiprazole, a new potential antipsychotic agent. Arzneimittelforschung. 1982;32(6):668-73. PubMed PMID: 6126197.

3: Lisciani R, Baldini A, Silvestrini B. General pharmacological properties of dapiprazole, a potential psychotropic agent. Arzneimittelforschung. 1982;32(6):674-8. PubMed PMID: 6126198.

4: Silvestrini B, Bonomi L, Lisciani R, Perfetti S, Belluci R, Massa F, Baldini A. Effects of dapiprazole on pupillary size and intraocular pressure in rabbits. Arzneimittelforschung. 1982;32(6):678-81. PubMed PMID: 6126199.

5: Connor CG, Campbell JB, Tirey WW. The clinical efficacy of Rev-Eyes in reversing the effects of pupillary dilation. J Am Optom Assoc. 1993 Sep;64(9):634-6. PubMed PMID: 7901259.